Secure Architecture is combining the physical and information technology fields by using security as the segue. Secure Architecture will provide security services using a unique method uncommonly known as 'transparent security' to test the security of a organizations at the perimeter, physical and logic level (information technology). Secure Architecture will employ Architects, Information Technology, and Security experts all under one roof. Transparent security by definition is a security process that can be easily overloaded, thus not being obvious.

Repindex stands for 'Representation Index'. It is a tool which facilitates analysis of the stream of language. By continuously searching selected Internet sources in real time, Repindex allows the user to track the development of the meaning of language items and to extract value. Repindex is also used to search for information over time and make comparisons between results in different groups, such as different language media. Repindex is based on Discourse Stream Analysis developed in Mark Perkins' PhD thesis. It relies on linguistic principles of identifying and describing patterns in large bodies of text.

The product is a MEMS and liquid crystal based optical switch for 'All Optical Networks'. One embodiment of the device deals with electromagnetic control of micro-mirrors, the second embodiment is on control of light math using an electro-optic material and the third embodiment deals with control of micro mirrors using liquid crystals. The product aims to remove the limitations of optical switches introduced by Lecent and Tellium by a considerable extent.

With US$33.2 billion spent on R&D in 2003 by U.S. drug companies alone, the number of drugs reaching the market is strikingly small. This is not surprising, since current 'out-of-the-box' target identification techniques make verification prohibitively long and costly. LAMA is a scientific consultancy providing customised data analysis and management solutions in drug discovery and disease treatment strategy development for high-throughput bioarray technologies in acadmeia, medical research and industry. Our innovative Gene Links Search Engine technology accelerates delivery of high-quality drug targets at lower identification and validation costs.

The InterGenomics Group seeks to transform modern medicine by incorporating complex genetic information into the care of individual patients. IgG has developed the first practical method to accurately predict and alter the genetic risk of common human diseases based on each person's unique Pattern of Polymorphism. IgG intends to market a series of predictive genetic tests that can not only reveal each person's genetic destiny, but also empower them with the knowledge to change it. The ability to predict and alter genetic risk will fundamentally transorm clinical medicine by introducing personalised disease prevention using predictive genetic tests.

InfoLog offers two products. The first allows easy and free paper publishing and reviewing for less experienced professionals and students. The second allows companies to efficiently build and manage databases of expert knowledge. Both products are based on the idea that the users of a database whould have maximum access, i.e. building, maintaining and querying that database should be an easy and simple process.

IDLink is an engineering start-up founded by Cambridge University PhD students intent on commercializing hardware-based wireless security devices. The proof-of-concept product will make computers fully secure from unauthorised access and will be a strong deterrent to theft. The technology will be developed for use in a variety of consumer electronics and licensed to Original Equipment Manufacturers, with projected revenues in 2006 of US$20M. Currently a patent application and a working prototype are being prepared, with licensing activities slated to start in Q3 2005. IDLink: the future of hacker-proof security.

Despite recent advances, the pharmaceutical industry is still pursuing expensive, and lengthy, approaches to the discovery of oncology drugs with limited efficacy and safety. This results in treatments which are unpleasant for the patient and susceptible to a reduction in effectiveness (resistance). Using innovative genetic manupulation tools, Horizon Discovery has access to a new technology which will allow itself, and partner pharmaceutical companies, to develop cost-effective medicines that are optimally tailored to specific cancer defects. By taking such a focused, 'personalised medicine', approach, Horizon Discovery will be able to reduce drug development costs and supply better medicines to the patient.

DVDNOW will enter the US$10bn DVD rental market. This is a mature market, recently revolutionised by www.netflix.com (US$600m revenue) and copycat businesses based on web subscriptions for mail-delivery DVDs. DVDNOW has identified a significant weakness in the Netflix et al. business model, which can be exploited at relatively low cost, using existing technologies coupled in a novel way. This allows a substantial expansion on the Netflix model market size, while further eroding the core of the bricks-and-mortar DVD rental market. In a global market where clone companies are competing simply on cost, DVDNOW confers a considerable competitive advantage.

Our proprietary technology combines nanotechnology and material science to provide simple, accurate and inexpensive security encryption through surface coating with DNA nano-enriched ink.